Yu Hara

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study

Rod Hughes, Eleni Rapsomaniki, Christer Janson et al. · Respiratory Medicine · 2022 · 43 citations · Full text

Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease

Hiroyuki Yagyu, Kota Murohashi, Yu Hara et al. · Journal of Thoracic Disease · 2020 · 36 citations · Full text

Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer

Takahisa Eriguchi, Atsuya Takeda, Naoko Sanuki et al. · Lung Cancer · 2017 · 34 citations

Adaptive Radiotherapy, Radiation Therapy, Medicine +6